1 Result: CureVac
CureVac's Patent Litigation Moves to Virginia, Ambrx Biopharma Receives Overweight Rating, Legend Biotech Gets Price Target Boost
May 19th, 2023
CureVac N.V. (Nasdaq: CVAC) has made an important announcement regarding the ongoing patent litigation initiated by Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX). CureVac's motion to transfer the litigation from the federal district court of Massachuset. Read more
Load More Content




Member Login